Company / FCF Margin
GYRE THERAPEUTICS, INC. FCF Margin History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-0.1%
FY2025
5-year range
-1152.8% / 5.6%
FY2021-FY2025
Trend
+97.3%
vs FY2024
Sector context
#61 of 133
Health Care
What the data says
At -0.1%, GYRE THERAPEUTICS, INC.'s fcf margin ranks #61 of 133 in the Health Care sector. Declined from 5.6% to -0.1% over the past 2 years.
Based on SEC 10-K filings.
-0.1% in FY2025 with a 3-year CAGR of -5.7%.
Declined from 5.6% to -0.1% over the past 2 years.
Health Care sector context is included.
FCF Margin over time
Growth rates
- 3-Year Change
- -5.7pp
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
#61 of 133 in Health CareTop 46% of 133This company -0.1% Sector average -632.8%
▼
+100.0% above sector average
Key checks
Key Insights
- In FY2025, fcf margin increased 97.3% year-over-year.
- Currently 632.7pp above the Health Care sector average.
- Peak fcf margin was recorded in FY2023.
- Lowest fcf margin in the period was in FY2018.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -0.1% | +97.3% |
| FY2024 | -5.6% | -201.3% |
| FY2023 | 5.6% | +0.0% |
| FY2022 | 5.6% | +100.5% |
| FY2021 | -1152.8% | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | -1961.0% | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026